A61K 2039/515
Animal cells
Official title: {Animal cells}
A61K2039/515 (Animal cells) appears on 1,711 US grants and 2,903 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,711
- Published applications
- 2,903
- Assignees
- 1,061
- Inventors
- 4,201
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 2 | 0 |
| 1997 | 11 | 0 |
| 1998 | 24 | 0 |
| 1999 | 22 | 0 |
| 2000 | 25 | 0 |
| 2001 | 37 | 9 |
| 2002 | 30 | 87 |
| 2003 | 32 | 112 |
| 2004 | 26 | 103 |
| 2005 | 29 | 99 |
| 2006 | 29 | 59 |
| 2007 | 28 | 56 |
| 2008 | 30 | 64 |
| 2009 | 35 | 80 |
| 2010 | 48 | 73 |
| 2011 | 44 | 88 |
| 2012 | 42 | 68 |
| 2013 | 33 | 58 |
| 2014 | 36 | 48 |
| 2015 | 39 | 92 |
| 2016 | 58 | 86 |
| 2017 | 62 | 152 |
| 2018 | 80 | 167 |
| 2019 | 121 | 166 |
| 2020 | 118 | 179 |
| 2021 | 128 | 213 |
| 2022 | 124 | 249 |
| 2023 | 99 | 210 |
| 2024 | 158 | 181 |
| 2025 | 89 | 122 |
| 2026 | 56 | 82 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- Method of treatment of cancer or tumour29 Sep 2026US 12,746,272 B2
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Suppression of diabetes using exosomes from stem cell programmed myeloid cells22 Sep 2026US 12,741,015 B2Creative Medical Technologies, Inc.
- Peptide tags for ligand induced degradation of fusion proteins15 Sep 2026US 12,735,463 B2Dana-Farber Cancer Institute, Inc.
- Cd4+ cytotoxic t cells and methods of use thereof8 Oct 2026US 2026/0308522 A1Dana-Farber Cancer Institute, Inc.
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
- Rcn1-derived teipp neoantigens and uses thereof24 Sep 2026US 2026/0285905 A1
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Methods for selectively stimulating proliferation of T cells341US 5,858,358 ADana-Farber Cancer Institute, Inc. · 1999
- CD9 antigen peptides and antibodies thereto326US 5,883,223 A1999
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Adoptive cell therapy with young T cells191US 8,383,099 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013